Analyst David Risinger from Leerink Partners sees the deal a...
Analyst David Risinger from Leerink Partners sees the deal as a 'transformative transaction' for Roivant and looks forward to hearing how the company plans to reinvest the cash.
Roivant, Pfizer Shares Rise as Roche Agrees to Buy Immunology Company for $7.1 Billion
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3162Followers
0Following
7910Visitors
Follow